Evidence from this study suggests that I-FABP, L-FABP, and defensins 5 and 6 may not serve as potential early biomarkers for MASLD diagnosis, but they can be used to describe organ damage such as liver and intestinal damage in children with MASLD. This evidence concerns the gene DEFA5 and metabolic dysfunction-associated steatotic liver disease.